The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis

BACKGROUND: The effectiveness of adding pembrolizumab to chemotherapy improve outcomes in newly diagnosed metastatic non-small-cell lung cancer (NSCLC). We aimed to evaluate the economic outcomes of first-line treatment by adding pembrolizumab to chemotherapy with and without the use of PD-L1 testin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Bin, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653112/
https://www.ncbi.nlm.nih.gov/pubmed/33209600
http://dx.doi.org/10.21037/tlcr-19-605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653112/
https://www.ncbi.nlm.nih.gov/pubmed/33209600
http://dx.doi.org/10.21037/tlcr-19-605

Ejemplares similares